| Trial ID: | L2726 |
| Source ID: | NCT06779929
|
| Associated Drug: |
Tirzepatide
|
| Title: |
Emulation of the Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT)
|
| Acronym: |
|
| Status: |
ACTIVE_NOT_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Tirzepatide|DRUG: Dulaglutide
|
| Outcome Measures: |
Primary: Composite CV outcome, Composite CV outcome includes myocardial infarction, stroke, and all-cause mortality., From treatment initiation to end of follow up, up to 48 months. |
|
| Sponsor/Collaborators: |
Sponsor: Brigham and Women's Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
50000
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2024-11-01
|
| Completion Date: |
2025-06-15
|
| Results First Posted: |
|
| Last Update Posted: |
2025-01-17
|
| Locations: |
Brigham and Women's Hospital, Boston, Massachusetts, 02120, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT06779929
|
